Comment on

• Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.

  George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT. George RE, et al. J Clin Oncol. 2005 Sep 20;23(27):6466-73. doi: 10.1200/JCO.2005.05.582. Epub 2005 Aug 22. J Clin Oncol. 2005. PMID: 16116152 Clinical Trial.
• Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.

  London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. London WB, et al. J Clin Oncol. 2005 Sep 20;23(27):6459-65. doi: 10.1200/JCO.2005.05.571. Epub 2005 Aug 22. J Clin Oncol. 2005. PMID: 16116153
• Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.

  Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK. Schmidt ML, et al. J Clin Oncol. 2005 Sep 20;23(27):6474-80. doi: 10.1200/JCO.2005.05.183. Epub 2005 Aug 22. J Clin Oncol. 2005. PMID: 16116154 Clinical Trial.